Form DEF 14A - Other definitive proxy statements:
SEC Accession No. 0001104659-22-052704
Filing Date
2022-04-29
Accepted
2022-04-29 06:07:35
Documents
8
Period of Report
2022-06-09

Document Format Files

Seq Description Document Type Size
1 DEF 14A tm223478-2_def14a.htm DEF 14A 1195003
2 GRAPHIC lg_mersanathera-4clr.jpg GRAPHIC 15589
3 GRAPHIC tm223478d1-bc_ceopay4c.jpg GRAPHIC 66073
4 GRAPHIC tm223478d1-bc_expertise4c.jpg GRAPHIC 176651
5 GRAPHIC tm223478d1-icon_crossbw.jpg GRAPHIC 487
6 GRAPHIC tm223478d1-icon_tickbw.jpg GRAPHIC 559
7 GRAPHIC tm223478d2-px_proxy1pg1bw.jpg GRAPHIC 1838894
8 GRAPHIC tm223478d2-px_proxy1pg2bw.jpg GRAPHIC 1517621
  Complete submission text file 0001104659-22-052704.txt   6172043
Mailing Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139
Business Address 840 MEMORIAL DRIVE CAMBRIDGE MA 02139 617-498-0020
Mersana Therapeutics, Inc. (Filer) CIK: 0001442836 (see all company filings)

EIN.: 000000000 | State of Incorp.: DE | Fiscal Year End: 1231
Type: DEF 14A | Act: 34 | File No.: 001-38129 | Film No.: 22869848
SIC: 2834 Pharmaceutical Preparations